An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04578444 |
|
Expanded Access Status :
Available
First Posted : October 8, 2020
Last Update Posted : November 10, 2022
|
Sponsor:
Zymeworks Inc.
Information provided by (Responsible Party):
Zymeworks Inc.
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
| Tracking Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| First Submitted Date | September 30, 2020 | ||||||||
| First Posted Date | October 8, 2020 | ||||||||
| Last Update Posted Date | November 10, 2022 | ||||||||
| Descriptive Information | |||||||||
| Brief Title | An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer | ||||||||
| Brief Summary | This is an intermediate-size Expanded Access Protocol (EAP) for use of zanidatamab (ZW25) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced biliary tract cancer (BTC) who are not eligible for other zanidatamab clinical trials, and who in the opinion of the treating oncologist, would potentially benefit from treatment with zanidatamab. | ||||||||
| Detailed Description | Not Provided | ||||||||
| Study Type | Expanded Access | ||||||||
| Expanded Access Type | Intermediate-size Population | ||||||||
| Intervention | Drug: Zanidatamab
Administered intravenously
Other Name: ZW25
|
||||||||
| Publications * | Not Provided | ||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
| Recruitment Information | |||||||||
| Expanded Access Status | Available | ||||||||
| Contacts |
|
||||||||
| Listed Location Countries | Not Provided | ||||||||
| Removed Location Countries | |||||||||
| Administrative Information | |||||||||
| NCT Number | NCT04578444 | ||||||||
| Current Responsible Party | Zymeworks Inc. | ||||||||
| Original Responsible Party | Same as current | ||||||||
| Current Study Sponsor | Zymeworks Inc. | ||||||||
| Original Study Sponsor | Same as current | ||||||||
| Collaborators | Not Provided | ||||||||
| Investigators | Not Provided | ||||||||
| PRS Account | Zymeworks Inc. | ||||||||
| Verification Date | November 2022 | ||||||||